<DOC>
	<DOCNO>NCT02445248</DOCNO>
	<brief_summary>This multi-center , phase II study determine efficacy safety CTL019 adult patient relapse refractory DLBCL .</brief_summary>
	<brief_title>Study Efficacy Safety CTL019 Adult DLBCL Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Written informed consent must obtain prior screen procedure Histologically confirm DLBCL last relapse ( central pathology review enrolment . . Relapsed refractory disease ≥2 line chemotherapy include rituximab anthracycline either fail autologous Hematopoietic stem cell transplantation ( ASCT ) , ineligible consent ASCT Measurable disease time enrollment Life expectancy ≥12 week Eastern Cooperative Oncology Group ( ECOG ) performance status either 0 1 screen Adequate organ function : Renal function define : A serum creatinine ≤1.5 x Upper Limit Normal ULN OR Estimated Glomerular Filtration Rate ( eGFR ) ≥ 60 mL/min/1.73 m2 Liver function define : Alanine Aminotransferase ( ALT ) ≤ 5 time Upper Limit Normal ( ULN ) age Bilirubin ≤ 2.0 mg/dl exception patient GilbertMeulengracht syndrome ; patient GilbertMeulengracht syndrome may include total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea pulse oxygenation &gt; 91 % room air Hemodynamically stable Left Ventricle Ejection Fraction ( LVEF ) ≥ 45 % confirm echocardiogram Multigated Radionuclide Angiography ( MUGA ) Adequate bone marrow reserve without transfusion define : Absolute neutrophil count ( ANC ) &gt; 1.000/mm3 Absolute lymphocyte count ( ALC ) ≥ 300/mm3 Platelets ≥ 50.000//mm3 Hemoglobin &gt; 8.0 g/dl Must apheresis product nonmobilized cell accept manufacture Women childbearing potential ( defined woman physiologically capable become pregnant ) male participant must agree use highly effective method contraception least 12 month follow CTL019 infusion CAR T cell longer present PCR two consecutive test Prior treatment prior antiCD19/antiCD3 therapy , antiCD19 therapy Treatment prior gene therapy product Active Central Nervous System ( CNS ) involvement malignancy Prior allogeneic HSCT Eligible consent ASCT Chemotherapy lymphodepleting chemotherapy within 2 week infusion Investigational medicinal product within last 30 day prior screen The following medication exclude : Steroids : Therapeutic dos steroid must stop &gt; 72 hour prior CTL019 infusion . However , follow physiological replacement dos steroid allow : &lt; 6 12 mg/m2/day hydrocortisone equivalent Immunosuppression : Any immunosuppressive medication must stop ≥ 4 week prior enrollment Antiproliferative therapy lymphodepleting chemotherapy within two week infusion Antibody use include antiCD20 therapy within 4 week prior infusion 5 halflives respect antibody , whichever long CNS disease prophylaxis must stop &gt; 1 week prior CTL019 infusion ( e.g . intrathecal methotrexate ) Prior radiation therapy within 2 week infusion Active replication prior infection hepatitis B active hepatitis C ( HCV RNA positive ) HIV positive patient Uncontrolled acute life threaten bacterial , viral fungal infection ( e.g . blood culture positive ≤ 72 hour prior infusion ) Unstable angina and/or myocardial infarction within 6 month prior screen Previous concurrent malignancy follow exception : Adequately treat basal cell squamous cell carcinoma ( adequate wound healing require prior study entry ) In situ carcinoma cervix breast , treat curatively without evidence recurrence least 3 year prior study A primary malignancy completely resect complete remission ≥ 5 year Investigational medicinal product within last 30 day prior screen Pregnant nursing ( lactate ) woman Intolerance excipients CTL019 cell product Cardiac arrhythmia control medical management Patients oral anticoagulation therapy Prior treatment adoptive T cell therapy Patients active neurological auto immune inflammatory disorder ( e.g . Guillain Barre Syndrome , Amyptrophic Lateral Sclerosis ) Other protocolrelated inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diffuse large B-cell lymphoma ,</keyword>
	<keyword>DLBCL ,</keyword>
	<keyword>Relapsed/refractory ,</keyword>
	<keyword>CTL019</keyword>
	<keyword>CART19</keyword>
	<keyword>CART</keyword>
	<keyword>CAR T cell</keyword>
	<keyword>Chimeric antigen receptor</keyword>
</DOC>